News

Though many patients with HPV-positive oropharyngeal cancer have been treated with cetuximab (Erbitux), results from the international De-ESCALaTE HPV trial showed that chemoradiotherapy, the current standard of care, is still the most effective.

The Food and Drug Administration has granted a priority review to the supplemental new drug application for ruxolitinib (Jakafi) to treat patients with acute graft-versus-host-disease (GVHD) who have had an inadequate response to corticosteroids.

The Food and Drug Administration (FDA) has granted a priority review to the oral chemotherapy TAS-102 (trifluridine/tipiracil; Lonsurf) for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.

Pet dogs help find cures for cancer.

The FDA has added 3 months to the review period for

To help patients and programs meet the challenges of affording cancer treatments, community cancer centers are expanding the role of financial advocates in their organizations. Financial advocates may be financial counselors, nurses, navigators, social workers; pharmacy technicians; practice managers, and others.

The Food and Drug Administration (FDA) approved Khapzory (levoleucovorin) injection, a folate analog for 3 indications.

The FDA has granted a priority designation to a supplemental new drug application (sNDA) for ibrutinib (Imbruvica) for use in combination with obinutuzumab (Gazyva) for the frontline treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The FDA has approved talazoparib (Talzenna) for patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer, according to Pfizer, the manufacturer of the PARP inhibitor.

The FDA has granted a breakthrough therapy designation to LOXO-292 for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options.

In an effort to help individuals gain access to breast health services, Barbells for Boobs and CancerCare®, the leading national cancer support organization, have officially launched the NYC Support Line.

The FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended approval of CT-P10, a biosimilar for the monoclonal antibody rituximab (Rituxin), for 3 non-Hodgkin lymphoma indications in a 16-0 vote.

For clinical nurse specialist and Oncology Nursing Society (ONS) member Anne Kolenic, DNP, APRN, AOCNS, her decision to pursue a DNP degree meant taking critical research results and implementing them to improve care at her institution.

The V Foundation for Cancer Research and Parker Institute for Cancer Immunotherapy Join as Sponsors

Grant to Be Funded by the V Foundation to Early Career Investigator at The University of Kansas Cancer Center

The Food and Drug Administration (FDA) approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) to expand its use in women and men aged 27 to 45 years.

The FDA has granted a priority review to the XPO1 inhibitor selinexor for the treatment of patients with penta-refractory multiple myeloma.

The Better Business Bureau (BBB) is warning consumers to make informed decisions about donating to breast cancer charities that businesses claim to be supporting during Breast Cancer Awareness Month.

Non-pharmacologic integrative medicine approaches such as aromatherapy and reflexology can dramatically reduce the pain and anxiety associated with cervical radiation therapy.

Durvalumab (Imfinzi) induced a clinically meaningful improvement in overall survival (OS) compared with placebo in patients with stage III, unresectable non–small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.

Immunotherapy pioneers James P. Allison, PhD, and Tasuku Honjo, MD, PhD, have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

Experts call for liver disease patients to get screened for cancer every 6 months.

In a recent survey, lung cancer survivors reported long-term symptoms, including shortness of breath, fatigue, short-term memory, and anxiety.

Here are the top 5 Oncology Nursing News stories for September 2018.

The FDA has granted the PARP inhibitor rucaparib (Rubraca) a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer (mCRPC) following at least 1 androgen receptor–directed therapy and taxane-based chemotherapy.

Brigatinib (Alunbrig) reduced the risk of disease progression or death by more than 50% compared to crizotinib (Xalkori) in adult patients with ALK-positive, locally advanced or metastatic non–small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor.

The FDA has approved a once-weekly dosing option of carfilzomib (Kyprolis) to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.

Combining alpelisib (BYL719) with fulvestrant (Faslodex) improved progression-free survival versus fulvestrant alone in postmenopausal women and men with hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutant advanced or metastatic breast cancer that progressed after aromatase inhibitor treatment with or without a CDK4/6 inhibitor.

A new test that identifies which bladder cancer tumors will become invasive could help reduce health care costs and over-treatment in patients.

The FDA has approved the PD-1 inhibitor cemiplimab (Libtayo) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for curative surgery or curative radiation.